All In Biotech

Drug Trial Radar · NCT00122382

Remission and Joint Damage Progression in Early Rheumatoid Arthritis

A Phase IIIB Multi-center, Randomized, Double-Blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate Naive Early Erosive RA Subjects Treated With Abatacept Plus Methotrexate Compared With Methotrexate

Last checked: Nov 20, 2026Latest source record: Nov 16, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,052 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,052

Actual

Start

Jul 2005

Primary completion

Feb 2008

Study completion Feb 2009

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jul 22, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a world wide study to evaluate the remission and joint damage in subjects treated with abatacept in addition to methotrexate versus subjects who receive methotrexate along with a placebo.

Conditions

  • Rheumatoid Arthritis

Interventions

  • AbataceptDrug

    abatacept 10 mg/kg IV monthly, methotrexate weekly, for 24 months

  • placeboDrug

    placebo IV, monthly, methotrexate weekly for 12 months followed by abatacept 10 mg/kg IV monthly, methotrexate weekly for 12 months

  • methotrexateDrug

    Oral, titrated to at least 15 mg per week not to exceed 20 mg per week administered every 28 days from Month 12 to Month 24

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants in DAS 28 C-reactive Protein (CRP) Remission at Month 12Time frame: Month 12
  2. Mean Change From Baseline in Radiographic Total Score to Month 12Time frame: Baseline, Month 12
  3. Number of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuations Due to AEs During the Open-Label PeriodTime frame: Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.
  4. Number of Participants With Serious Adverse Events Reported During the Open-Label PeriodTime frame: Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.
  5. Number of Participants With SAEs With an Outcome of Death During the Open-label PeriodTime frame: Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.
  6. Incidence Rates of Autoimmune Disorders in ABA-Treated ParticipantsTime frame: Double Blind Period (+56 days post last dose in double-blind period or start of open-label period, whichever came first). Open-label period (56 days post last dose in the open-label period or start of maintenance sub-study, whichever came first).
  7. Incidence Rates of Infections and Infestations of Adverse Events in ABA-Treated ParticipantsTime frame: Double Blind Period (+56 days post last dose in double-blind period or start of the open-label period, whichever came first). Open-label period (56 days post last dose in open-label period or start of maintenance sub-study, whichever came first).
  8. Incidence Rates of Malignant Neoplasm Adverse Events in ABA-Treated ParticipantsTime frame: Double Blind Period (+56 days post last dose in double-blind period or start of the open-label period, whichever came first). Open-label period (56 days post last dose in open-label period or start of maintenance sub-study, whichever came first).
  9. Number of Participants With a Serious Acute-Infusional AE of Anaphylactic Shock During Open-Label PeriodTime frame: Open-Label Period (Month 12 to Month 24)
  10. Number of Participants With Select Blood Chemistry Laboratory Values Meeting the Marked Abnormality Criteria During the Open-Label PeriodTime frame: Continuously through open-label period (from Month 12 to Month 24). Includes data up to 56 days post last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.
  11. Number of Participants With Hematology Laboratory Values Meeting the Marked Abnormality Criteria During the Open-Label PeriodTime frame: Continuously from start of open-label period up to 56 days post the last dose in the open-label period or start of the maintenance sub-study, whichever occurred first.

Locations

89 sites in 18 countries. Site status is shown where the registry gives one.

  • Rheumatology Associates Of North Alabama

    Huntsville, Alabama

  • Talbert Medical Group

    Huntington Beach, California

  • Arthritis Assoc And Osteo Ctr Of Col Sprgs

    Colorado Springs, Colorado

  • New England Research Associates, Llc

    Trumbull, Connecticut

  • Diagnostic Rheumatology And Research

    Indianapolis, Indiana

  • Osteoporosis And Clinical Trials Center

    Cumberland, Maryland

  • Malamet & Klein, Md, Pa

    Hagerstown, Maryland

  • Arthritis Center Of Nebraska

    Lincoln, Nebraska

  • Regional Rheumatology Associates

    Binghamton, New York

  • Carolina Bone & Joint

    Charlotte, North Carolina

  • Physicians East, Pa

    Greenville, North Carolina

  • Carolina Pharmaceutical Research

    Statesville, North Carolina

  • Lion Research

    Norman, Oklahoma

  • Health Research Of Oklahoma

    Oklahoma City, Oklahoma

  • Lynn Health Sciences Institute

    Oklahoma City, Oklahoma

  • Altoona Center For Clinical Research

    Duncansville, Pennsylvania

  • Low Country Research Center

    Charleston, South Carolina

  • Walter F Chase Md Pa

    Austin, Texas

  • Arthritis Clinic Of Northern Virginia, P.C.

    Arlington, Virginia

  • Local Institution

    Malvern, Victoria, Australia

  • Local Institution

    Shenton Park, Western Australia, Australia

  • Local Institution

    Antwerp, Belgium

  • Local Institution

    Brussels, Belgium

  • Local Institution

    Brussels, Belgium

  • Local Institution

    Hasselt, Belgium

  • Local Institution

    Leuven, Belgium

  • Local Institution

    Goiânia, Goiás, Brazil

  • Local Institution

    Curitiba, Paraná, Brazil

  • Local Institution

    Rio de Janeiro - Rj, Rio de Janeiro, Brazil

  • Local Institution

    Porto Alegre, Rio Grande do Sul, Brazil

  • Local Institution

    São Paulo, São Paulo, Brazil

  • Local Institution

    São Paulo, São Paulo, Brazil

  • Local Institution

    St. John's, Newfoundland and Labrador, Canada

  • Local Institution

    Kitchener, Ontario, Canada

  • Local Institution

    Toronto, Ontario, Canada

  • Local Institution

    Montreal, Quebec, Canada

  • Local Institution

    Québec, Quebec, Canada

  • Local Institution

    Sherbrooke, Quebec, Canada

  • Local Institution

    Saskatoon, Saskatchewan, Canada

  • Local Institution

    Prague, Czechia

Showing 40 of 89 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.